Endoscopic Septoplasty in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Adult and pediatric patients (typically ≥16 years, after nasal skeletal maturity) with symptomatic nasal obstruction due to a clinically and radiologically confirmed deviated nasal septum unresponsive to ≥3 months of conservative medical management

• Patients with a Nasal Obstruction Symptom Evaluation (NOSE) Scale score ≥55 (severe obstruction), correlating with significant quality-of-life impairment

• Individuals with posterior or high septal deviations (bony spurs at the vomerine-perpendicular plate junction) that are inaccessible by conventional headlight technique and represent ideal candidates specifically for the endoscopic approach

• Patients requiring concurrent FESS for chronic rhinosinusitis (CRS), who need septal correction to optimize surgical access and postoperative sinus visualization

• Patients with OSA in whom nasal obstruction is a documented contributing factor (AHI >5 on PSG), where septoplasty is part of a multilevel airway management strategy

• Patients seeking combined septorhinoplasty for functional-cosmetic correction in a single session

• REQUIRED PREOPERATIVE DIAGNOSTICS:

• CT scan of paranasal sinuses (non-contrast, 1 mm axial slices with coronal and sagittal reconstructions) — mandatory to map septal deviation, identify associated sinus disease, and assess anatomical variants (Haller cells, Onodi cells, paradoxical middle turbinate)

• Diagnostic rigid nasal endoscopy in-clinic (0° and 30° endoscopes) to confirm clinical deviation and assess mucosal health

• Acoustic rhinometry and/or anterior active rhinomanometry (AAR) to objectively quantify nasal airway resistance before and after decongestion (evaluating reversibility)

• Full blood count (FBC), coagulation profile (PT, aPTT, INR), metabolic panel, blood group and cross-match

• ECG and anesthesia fitness assessment for patients >40 years or with cardiovascular comorbidities

• Polysomnography (PSG) or HSAT if OSA is suspected on clinical screening (Epworth Sleepiness Scale, STOP-BANG questionnaire)

• Allergy skin-prick testing or serum specific IgE panel if allergic rhinitis is a concurrent diagnosis

• CONTRAINDICATIONS:

• Active nasal infection (acute bacterial sinusitis, vestibulitis) — surgery must be deferred until resolved with antibiotherapy

• Uncontrolled bleeding diathesis or anticoagulant therapy that cannot be safely bridged perioperatively

• Pregnancy (relative contraindication; elective surgery deferred to postpartum period)

• Active granulomatous disease of the nasal septum (Wegener's granulomatosis/GPA, sarcoidosis, tuberculosis, cocaine-induced septal necrosis) — underlying disease must be controlled prior to surgery

• Patients with unrealistic cosmetic expectations where deviation is minimal and symptoms may be adequately managed medically

• Pediatric patients <16 years (generally relative contraindication unless severe functional impairment exists, given ongoing nasal skeletal development)

STANDARD CONVENTIONAL SEPTOPLASTY (Comparator Baseline):

Traditional septoplasty uses a headlight and Killian or hemitransfixion incision to elevate bilateral mucoperichondrial flaps and excise or reposition deviated cartilage and bone. While effective for anterior deviations, visualization of posterior bony spurs, the perpendicular plate of the ethmoid, and vomerine deviations is limited, requiring tactile rather than visual surgical guidance. Reported revision rates for conventional septoplasty range from 5–15% in published series.

ENDOSCOPIC SEPTOPLASTY (Primary Advanced Approach):

Performed using a rigid nasal endoscope (0° for anterior work; 30° and 45° for posterior and superior deviations), endoscopic septoplasty provides 4–8× optical magnification and high-definition visualization transmitted to a monitor, allowing precise, targeted mucosal flap elevation with fine Freer elevators and Cottle dissectors, controlled cartilage scoring with a 15-blade or Colorado monopolar tip, direct-vision chisel and mallet osteotomy for bony septal deformities, and microdebrider-assisted tissue removal in complex cases. The technique can be performed under general anesthesia or local anesthesia with IV sedation (propofol/midazolam/fentanyl) in select patients. Operative time is typically 30–90 minutes depending on deviation complexity and concurrent procedures.

COMBINED ENDOSCOPIC SEPTOPLASTY + FESS:

The most commonly performed combined procedure in patients with coexistent CRS. Septoplasty provides the anatomical access corridor for FESS, enabling middle meatal antrostomy, anterior and posterior ethmoidectomy, sphenoidotomy, and frontal recess surgery (Draf I–IIB) under the same anesthetic. Powered instrumentation (microdebrider at 1,500–2,500 RPM), image-guided navigation systems (Stryker NAV or Medtronic StealthStation ENT), and intraoperative fluorescence-guided mucosal assessment are available at premium centers in both India and the UAE.

COMBINED SEPTOPLASTY + TURBINATE REDUCTION:

Inferior turbinate hypertrophy (bony or mucosal) is present in up to 75% of patients with DNS as a compensatory phenomenon. Concurrent inferior turbinoplasty options include: (1) Submucosal diathermy (SMD), (2) Radiofrequency ablation (RFA/Coblation — temperature-controlled, 60–70°C, minimizing mucosal damage), (3) Microdebrider-assisted inferior turbinoplasty (MAIT), or (4) Partial inferior turbinectomy in refractory cases. Turbinate reduction is performed endoscopically in the same session to maximize nasal patency.

SEPTORHINOPLASTY (Functional-Cosmetic Combined Approach):

For patients with concurrent external nasal deformity, septoplasty is integrated with open or closed rhinoplasty techniques including cartilage grafting (spreader grafts, columellar strut, batten grafts harvested from septal, auricular conchal, or costal cartilage) to simultaneously correct the deviated septum, the external nasal pyramid, and the internal nasal valve angle. The Cottle maneuver is used preoperatively to identify internal nasal valve compromise.

INTRAOPERATIVE ADJUNCTS & TECHNOLOGIES:

• Image-Guided Navigation Surgery (IGS/IGN): Electromagnetic or optical navigation (Medtronic StealthStation, Brainlab Kolibri) used in revision cases or complex posterior deviations near the skull base, reducing the risk of inadvertent cribriform plate or orbital lamina papyracea injury.

• Powered Instrumentation: Microdebrider (Medtronic XPS or Stryker IPC) for precise soft-tissue debridement.

• Absorbable Septal Splints / Hemostatic Packing: Merocel packs, Rapid Rhino inflatable splints, or absorbable FloSeal/Surgicel hemostatic matrix agents to minimize postoperative bleeding and synechia formation, often eliminating the need for painful non-absorbable packing removal.

• Piezoelectric Ultrasonic Bone Surgery: Emerging modality (Piezosurgery, Mectron) for precise bony septum osteotomy with minimal thermal spread and mucosal sparing, available at select academic ENT centers.

POSTOPERATIVE MEDICAL MANAGEMENT:

Antibiotics (amoxicillin-clavulanate or cefuroxime for 5–7 days), intranasal saline irrigation (high-volume, isotonic or hypertonic — twice daily from day 2), intranasal corticosteroid spray (resumed at week 2–3), and systemic analgesics (paracetamol/NSAIDs; opioids rarely required). Nasal debridement under endoscopic visualization at 1–2 weeks postoperatively to remove crusting and blood clot, promoting mucociliary clearance and reducing synechia risk.

PHASE 1 — REMOTE PRE-ASSESSMENT (Weeks 1–3 before travel):

• Submit medical records, prior CT scans, and rhinoscopy reports to the GAF Healthcare clinical coordination team for remote review by the treating ENT surgeon.

• Receive a personalized treatment plan, cost estimate, and hospital shortlist within 48–72 hours.

• Virtual teleconsultation with the operating ENT surgeon to discuss surgical approach, concurrent procedures (FESS/turbinate reduction), anesthesia preference, and expectations.

• Initiate perioperative medication adjustments: cease aspirin, NSAIDs, anticoagulants, herbal supplements (ginkgo, garlic, vitamin E) at least 7–10 days preoperatively per hematological risk assessment.

• Obtain e-Medical Visa (India) or UAE entry visa facilitated by GAF Healthcare — typical processing 3–7 business days.

PHASE 2 — ARRIVAL & PREOPERATIVE WORKUP (Day 1–2 in country):

• Airport reception by GAF Healthcare's dedicated care coordinator; transfer to hospital or partnered accommodation.

• Same-day or next-day in-hospital preoperative workup: blood investigations (FBC, coagulation, metabolic panel), ECG, anesthesia assessment, and repeat diagnostic nasal endoscopy by the operating surgeon.

• Review CT scans; if not done recently (within 3–6 months), repeat CT paranasal sinuses at the hospital radiology department.

• Preoperative consent, surgical planning confirmation, NPO (nil per os) instruction — typically nothing by mouth from midnight before the procedure.

PHASE 3 — SURGICAL DAY (Day 2 or 3):

• Admission to day-surgery unit or inpatient ward 2 hours pre-procedure.

• Anesthesia induction (general anesthesia or IV sedation with local infiltration of 1% lidocaine + 1:100,000 epinephrine for mucosal decongestion and hemostasis).

• Endoscopic Septoplasty performed: 30–90 minutes operative time.

• Placement of absorbable or non-absorbable nasal packing/splints; patients are monitored in the recovery room for 1–2 hours.

• For day-surgery cases: discharge same evening with oral antibiotics, analgesics, and saline spray. For combined FESS or more complex cases: overnight hospital stay (1–2 nights).

PHASE 4 — EARLY POSTOPERATIVE RECOVERY IN COUNTRY (Days 3–7):

• Day 1–2 post-op: Expect nasal congestion (packs/splints in situ), mild facial pressure, blood-tinged nasal discharge, and periorbital bruising if rhinoplasty was combined. Ice packs applied to the nasal bridge for first 48 hours. Head-of-bed elevation at 30–45° recommended.

• Day 2–5: If non-absorbable packing used, removal is performed by the surgeon (Day 2–5) — this may cause brief discomfort but provides immediate relief of nasal obstruction.

• Day 7 (First postoperative endoscopic debridement): Surgeon removes crusting, inspects mucosal healing, and ensures adequate nasal airway under endoscopic visualization. This appointment is mandatory before fit-to-fly clearance.

• Continue high-volume saline nasal irrigation (e.g., NeilMed Sinus Rinse or Neti pot) twice daily — this is the single most important postoperative intervention for mucosal healing and crust prevention.

PHASE 5 — FIT-TO-FLY ASSESSMENT & DEPARTURE (Days 10–14):

• Clinical review by the operating ENT surgeon at Day 10–14. Fit-to-fly is confirmed when: (1) no active bleeding, (2) nasal airway is adequately patent on endoscopy, (3) no signs of septal hematoma, perforation, or infection.

• Flying considerations: Cabin pressure changes during ascent/descent may cause transient ear/nasal pressure discomfort. Recommend decongestant nasal spray (oxymetazoline 0.05%) used 30 minutes before takeoff and landing during the return flight (for a maximum of 3–5 days of use only, to avoid rebound congestion/rhinitis medicamentosa).

• Patients typically receive a written medical discharge summary, operative report, and pathology reports (if tissue sent for histology) for continuity of care with their home physician.

PHASE 6 — LONG-TERM RECOVERY AT HOME (Weeks 3–12+):

• Week 2–3: Resume intranasal corticosteroid spray. Return to office-based work by Day 7–14. Avoid strenuous physical exertion, contact sports, and nose-blowing for 4–6 weeks.

• Week 4–6: Majority of mucosal edema resolves; significant improvement in nasal breathing typically noted. Sleep quality and OSA-related parameters show measurable improvement.

• Week 6–12: Complete mucosal healing and crust clearance. Final functional outcomes assessed at 3-month follow-up (rhinomanometry, NOSE scale re-evaluation).

• Virtual follow-up teleconsultation at Week 3 and Month 3 arranged by GAF Healthcare with the operating surgeon.